Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System
Sarah M. Carpanini, Megan Torvell, B. Paul Morgan
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 180

Showing 1-25 of 180 citing articles:

Complement in neurological disorders and emerging complement-targeted therapeutics
Marinos C. Dalakas, Harry Alexopoulos, Peter J. Spaeth
Nature Reviews Neurology (2020) Vol. 16, Iss. 11, pp. 601-617
Open Access | Times Cited: 261
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Nicole D. Schartz, Andrea J. Tenner
Journal of Neuroinflammation (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 208
Neuroinflammation in Alzheimer’s Disease
Isaac G. Onyango, Gretsen Velezmoro Jáuregui, Mária Čarná, et al.
Biomedicines (2021) Vol. 9, Iss. 5, pp. 524-524
Open Access | Times Cited: 204
Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption
Iosif Pediaditakis, Konstantia Kodella, Dimitris V. Manatakis, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 162
Neuroinflammation in Acute Ischemic and Hemorrhagic Stroke
Diana Alsbrook, Mario Di Napoli, Kunal Bhatia, et al.
Current Neurology and Neuroscience Reports (2023) Vol. 23, Iss. 8, pp. 407-431
Open Access | Times Cited: 145
New Avenues for the Treatment of Huntington’s Disease
Amy Kim, Kathryn M. Lalonde, Aaron Truesdell, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8363-8363
Open Access | Times Cited: 138
Complement in the Brain: Contributions to Neuroprotection, Neuronal Plasticity, and Neuroinflammation
Suzanne S. Bohlson, Andrea J. Tenner
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 431-452
Open Access | Times Cited: 47
The Importance of Complement-Mediated Immune Signaling in Alzheimer’s Disease Pathogenesis
André F. Batista, Khyrul Khan, Maria-Tzousi Papavergi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 817-817
Open Access | Times Cited: 24
Compendium of current complement therapeutics
Wioleta M. Zelek, Long Xie, B. Paul Morgan, et al.
Molecular Immunology (2019) Vol. 114, pp. 341-352
Open Access | Times Cited: 139
Mechanisms underlying progression in multiple sclerosis
Martina Absinta, Hans Lassmann, Bruce D. Trapp
Current Opinion in Neurology (2020) Vol. 33, Iss. 3, pp. 277-285
Open Access | Times Cited: 128
Disease-modifying therapies in amyotrophic lateral sclerosis
Adriano Chiò, Letizia Mazzini, Gabriele Mora
Neuropharmacology (2020) Vol. 167, pp. 107986-107986
Closed Access | Times Cited: 97
Blood-Brain Barrier: More Contributor to Disruption of Central Nervous System Homeostasis Than Victim in Neurological Disorders
Minjia Xiao, Zhi Jie Xiao, Binbin Yang, et al.
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 90
Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
Khalil Mallah, Christine Couch, Davis Borucki, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 71
Present and future of microglial pharmacology
Eva Šimončičová, Elisa Gonçalves de Andrade, Haley A. Vecchiarelli, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 8, pp. 669-685
Open Access | Times Cited: 62
The role of damage associated molecular pattern molecules (DAMPs) and permeability of the blood-brain barrier in depression and neuroinflammation
María Fernanda Serna-Rodríguez, Sofía Bernal‐Vega, José Alfonso Ontiveros-Sánchez de la Barquera, et al.
Journal of Neuroimmunology (2022) Vol. 371, pp. 577951-577951
Closed Access | Times Cited: 62
Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection
Menizibeya O. Welcome, Nikos E. Mastorakis
Inflammopharmacology (2021) Vol. 29, Iss. 4, pp. 939-963
Open Access | Times Cited: 57
New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022
JingSi Jiang, Yan Wang, Min Deng
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 50
Compstatins: the dawn of clinical C3-targeted complement inhibition
Christina Lamers, Dimitrios C. Mastellos, Daniel Ricklin, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 8, pp. 629-640
Open Access | Times Cited: 49
Mechanistic insight into female predominance in Alzheimer’s disease based on aberrant protein S-nitrosylation of C3
Hongmei Yang, Chang-ki Oh, Haitham Amal, et al.
Science Advances (2022) Vol. 8, Iss. 50
Open Access | Times Cited: 42
Mass Spectrometry–Based Proteomics Analysis of Human Substantia Nigra From Parkinson's Disease Patients Identifies Multiple Pathways Potentially Involved in the Disease
Yura Jang, Olga Pletniková, Juan C. Troncoso, et al.
Molecular & Cellular Proteomics (2022) Vol. 22, Iss. 1, pp. 100452-100452
Open Access | Times Cited: 39
The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics
Manaswini Ghosh, Soumendra Rana
International Immunopharmacology (2023) Vol. 118, pp. 110081-110081
Closed Access | Times Cited: 28
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis
Kiterie M. E. Faller, Helena Chaytow, Thomas H. Gillingwater
Nature Reviews Neurology (2025) Vol. 21, Iss. 2, pp. 86-102
Closed Access | Times Cited: 1
Traumatic brain injury increases plasma astrocyte‐derived exosome levels of neurotoxic complement proteins
Edward J. Goetzl, Kristine Yaffe, Carrie Peltz, et al.
The FASEB Journal (2020) Vol. 34, Iss. 2, pp. 3359-3366
Open Access | Times Cited: 66
Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics
Christopher J. Patriquin, Kevin H.M. Kuo
Transfusion Medicine Reviews (2019) Vol. 33, Iss. 4, pp. 256-265
Closed Access | Times Cited: 60
Complement Has Brains—Do Intracellular Complement and Immunometabolism Cooperate in Tissue Homeostasis and Behavior?
Natalia Kunz, Claudia Kemper
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top